MG 014
Alternative Names: MG-014Latest Information Update: 07 Jun 2022
Price :
$50 *
At a glance
- Originator Shanghai Mabgeek Biotech
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Immunological disorders; Respiration disorders
Most Recent Events
- 25 May 2022 Preclinical trials in Immunological disorders in China (Parenteral)(Shanghai Mabgeek Biotechnology pipeline, May 2022)
- 25 May 2022 Preclinical trials in Respiration disorders in China (Parenteral)(Shanghai Mabgeek Biotechnology pipeline, May 2022)
- 25 May 2022 Shanghai Mabgeek Biotechnology plans a phase I trial for Respiratory and immunological disorders in 2022(Shanghai Mabgeek Biotechnology pipeline, May 2022)